William Larry Gluck

530 total citations
24 papers, 409 citations indexed

About

William Larry Gluck is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, William Larry Gluck has authored 24 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in William Larry Gluck's work include Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (4 papers) and RNA modifications and cancer (4 papers). William Larry Gluck is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (4 papers) and RNA modifications and cancer (4 papers). William Larry Gluck collaborates with scholars based in United States, Netherlands and France. William Larry Gluck's co-authors include JB Weinberg, Wendell F. Rosse, Dana V. Devine, Kimberly Denis-Mize, Alan R. Yuen, Deborah Hurst, Susan E. Wilson, Barbara Tong, Alexandra M. Levine and Mark A. Dayton and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

William Larry Gluck

24 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Larry Gluck United States	8	172	155	111	94	68	24	409
Manfred Ahlgrimm Germany	8	90 0.5×	50 0.3×	76 0.7×	58 0.6×	56 0.8×	17	272
Marcin Pasiarski Poland	11	194 1.1×	170 1.1×	83 0.7×	95 1.0×	86 1.3×	33	413
Mecide Gharibo United States	12	197 1.1×	49 0.3×	175 1.6×	71 0.8×	57 0.8×	34	400
Dominique Cazals France	9	247 1.4×	98 0.6×	138 1.2×	143 1.5×	40 0.6×	11	525
Tomoko Kawabata Japan	10	60 0.3×	108 0.7×	110 1.0×	45 0.5×	45 0.7×	36	428
H Urbańska-Ryś Poland	12	159 0.9×	99 0.6×	111 1.0×	156 1.7×	197 2.9×	24	449
Gabriel Prolla Brazil	8	196 1.1×	118 0.8×	97 0.9×	158 1.7×	41 0.6×	17	427
Simon Hallam United Kingdom	9	161 0.9×	122 0.8×	179 1.6×	56 0.6×	52 0.8×	23	400
Olav Erich Yri Norway	10	218 1.3×	119 0.8×	58 0.5×	202 2.1×	120 1.8×	22	484
Birgit Haier Germany	7	244 1.4×	298 1.9×	84 0.8×	204 2.2×	42 0.6×	11	556

Countries citing papers authored by William Larry Gluck

Since Specialization

Citations

This map shows the geographic impact of William Larry Gluck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Larry Gluck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Larry Gluck more than expected).

Fields of papers citing papers by William Larry Gluck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Larry Gluck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Larry Gluck. The network helps show where William Larry Gluck may publish in the future.

Co-authorship network of co-authors of William Larry Gluck

This figure shows the co-authorship network connecting the top 25 collaborators of William Larry Gluck. A scholar is included among the top collaborators of William Larry Gluck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Larry Gluck. William Larry Gluck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Edenfield, William J., Ki Y. Chung, Mark Allen O’Rourke, et al.. (2021). A PhaseIIStudy of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers. The Oncologist. 26(9). e1499–e1507. 7 indexed citations

Gluck, William Larry, Sean Callahan, Antine E. Stenbit, et al.. (2020). Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19. Respiratory Medicine. 175. 106188–106188. 31 indexed citations

Gluck, William Larry, Mrinal M. Gounder, Richard C. Frank, et al.. (2019). Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investigational New Drugs. 38(3). 831–843. 90 indexed citations

Diamond, Jennifer R., Pavani Chalasani, Eleni Andreopoulou, et al.. (2018). Preliminary report of a phase 1b/2a trial, an oral inhibitor of phosphorylated P68 (P-p68) which mediates β-catenin nuclear translocation in advanced triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 36(15_suppl). 1097–1097. 2 indexed citations

Gluck, William Larry, Julie Martin, W. Jeffrey Edenfield, Ki Y. Chung, & David Arguello. (2017). Prolonged response of widely metastatic HER2-positive colon cancer to trastuzumab therapy. 6(2). 57–61. 2 indexed citations

Gutierrez, Martin, S. Gail Eckhardt, William Larry Gluck, & Ely Benaim. (2016). RX-5902: A phosphorylated p68 targeting agent to treat subjects with advanced solid tumors.. Journal of Clinical Oncology. 34(4_suppl). TPS778–TPS778. 2 indexed citations

Eckhardt, Sabine, William Larry Gluck, Martin Gutierrez, et al.. (2016). Results of a phase I study of RX-5902: An orally bioavailable inhibitor of phosphorylated P68, targeting solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2554–2554. 2 indexed citations

Chiang, Anne C., Charles M. Rudin, Alexander I. Spira, et al.. (2016). Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology. 34(15_suppl). 8564–8564. 7 indexed citations

O’Reilly, Eileen M., Lon Smith, Johanna C. Bendell, et al.. (2015). Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 33(3_suppl). 278–278. 10 indexed citations

10.

Patel, Manish R., Erika Hamilton, Patricia LoRusso, et al.. (2015). Abstract CT233: A phase I study evaluating continuous and intermittent AZD2014 in combination with fulvestrant in patients with ER+ advanced metastatic breast cancer. Cancer Research. 75(15_Supplement). CT233–CT233. 3 indexed citations

11.

Pietanza, M. Catherine, Alexander I. Spira, Robert M. Jotte, et al.. (2015). Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology. 33(15_suppl). 7508–7508. 10 indexed citations

12.

Gluck, William Larry, S. Gail Eckhardt, Martin Gutierrez, Christine B. Peterson, & Ely Benaim. (2015). 344 Single agent supoinoxin targeting phosphorylated p-68 preliminary phase 1 data. European Journal of Cancer. 51. S68–S69. 1 indexed citations

13.

Spira, Alexander I., Robert M. Jotte, Shirish M. Gadgeel, et al.. (2014). Phase 1B Trial of Anti-Notch 2/3 Antibody Omp-59R5 in Combination with Etoposide and Cisplatin (Ep) in Patients (Pts) with Untreated Extensive-Stage Small-Cell Lung Cancer (Ed-Sclc): the Pinnacle Study. Annals of Oncology. 25. iv514–iv514. 1 indexed citations

14.

Reynolds, C., Alexander I. Spira, William Larry Gluck, et al.. (2011). Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients.. Journal of Clinical Oncology. 29(15_suppl). 7549–7549. 3 indexed citations

15.

Gluck, William Larry, Deborah Hurst, Alan R. Yuen, et al.. (2004). Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma. Clinical Cancer Research. 10(7). 2253–2264. 127 indexed citations

16.

Hantel, Alexander, Catherine M. Tangen, William Larry Gluck, & John S. Macdonald. (1994). Phase II trial of piroxantrone in gastric carcinoma. Investigational New Drugs. 12(2). 159–161. 4 indexed citations

17.

Gluck, William Larry. (1990). Thyroid and Parathyroid Cancer. Otolaryngologic Clinics of North America. 23(6). 1181–1197. 2 indexed citations

18.

Gluck, William Larry & Jason B. Weinberg. (1987). 1α,25 Dihydroxyvitamin D3 and Mononuclear Phagocytes: Enhancement of Mouse Macrophage and Human Monocyte Hydrogen Peroxide Production Without Alteration of Tumor Cytolysis. Journal of Leukocyte Biology. 42(5). 498–503. 16 indexed citations

19.

Devine, Dana V., William Larry Gluck, Wendell F. Rosse, & JB Weinberg. (1987). Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone.. Journal of Clinical Investigation. 79(1). 314–317. 45 indexed citations

20.

Gluck, William Larry. (1987). Thyroid and Parathyroid Cancer. Clinics in Geriatric Medicine. 3(4). 729–742. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact